A 2-day workshop co-organized by the Health and Environmental Sciences Institute, Health Canada, and McGill University to address current and potential applications of genomics in cancer risk assessment.
The HESI Genetic Toxicology Technical Committee (GTTC) will hold the workshop in conjunction with the Genetic Toxicology Association (GTA) annual meeting on 10 May 2017 in Newark, Delaware. Workshop topics will include mini adverse outcome pathways for genotoxic modes of actions, methods to determine the mode of action of genotoxic agents, and how to use new technologies to establish the mode of action of genotoxicity for new chemical entities. This event is HESI Future Leaders Travel Award (FLT) eligible!
The HESI Emerging Issues sub-committee on cell therapies safety, CT-TRACS (Cell Therapy – TRAcking, Circulation, & Safety) is pleased to present a session selected based on scientific merit, at the International Society of Cellular Therapy (ISCT) annual meeting in London on May 6th, 15:00-16:30.
View the meeting website and access the full program here: http://isct2017.com
This workshop will consider new strategies to identify developmental hazards taking into account the current state of science which may include alternative possibilities or improvements to the current Segment 2 design. These considerations could include the use of new technology to overcome some of the limitations in predicting human response with current animal models or completely new radical approach to developmental toxicity hazard identification. These may range from having a critical paradigm to deciding when non-clinical studies are needed to the use of biotechnology and computational models or hazard characterization. Working groups can consider either strategy, or combinations of the two.
The field of immunotoxicology is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and toxicology, the need for continued training and interdisciplinary interactions are critical for those who work within this field. This is essential both for those with an immunology background who seek to apply this expertise to drug development and safety, as well as those who wish to enhance their current drug safety expertise with a deeper understanding of immunology. This event is HESI Future Leaders Travel Award (FLT) eligible!